Comparison

Injectable vs Oral GLP-1 Medications

Three categories, not two

Approved injectables. Zepbound, Mounjaro, Wegovy, Ozempic. Every efficacy figure in this field comes from trials of these.

Approved orals. Orforglipron and oral semaglutide tablets. Each went through its own trial programme for the oral formulation, because oral delivery of peptides is a genuinely hard pharmacological problem that had to be solved and then demonstrated.

Compounded orals and sublinguals. ODTs, lozenges, liquid drops. No trial has tested any of them. Bioavailability for these specific formulations is unpublished.

Why the pharmacology matters

An injected peptide bypasses the digestive system. Taken by mouth it faces stomach acid, digestive enzymes and poor intestinal absorption. That is why approved oral versions require specific formulation technology, and why oral doses are numerically very different from injected ones.

A compounded ODT is not an injectable dose in tablet form. How much drug reaches the bloodstream is the entire question, and for these products it has not been published.

The prices make the case awkward

Approved orals: $149 for orforglipron at the 0.8 mg starter dose, $149 for oral Wegovy tablets. Both rise with dose.

Compounded orals and sublinguals in our dataset: $165 to $369. NexLife (opens nexlife.us in a new tab) ODT semaglutide at $165 and tirzepatide at $199, both verified. Henry Meds oral semaglutide at $249 and oral tirzepatide at $349. Shed sublingual formats at $199 and $229. MEDVi oral semaglutide at $369. These Henry Meds figures were taken from third-party publications and are withdrawn pending a capture of our own; see COR-009.

Every one of those is above the approved oral price at its starting dose, and the approved products have published data.

The practical trade

Injectables have the evidence and, at the low end of the compounded market, the lower price. Approved orals avoid needles and now cost $149 at the entry dose. Compounded orals avoid needles, cost more than approved orals, and have no evidence at all.

If needle avoidance is the driver, the approved orals are the route with data behind them. If price is the driver, the cheapest options are compounded injectables. The compounded oral category is currently the one that is hardest to justify on either axis.

Flat-rate structures make dose escalation financially neutral. NexLife holds one price across every covered dose, from $186 a month. Its plan pages state the terms before intake.

Questions readers actually ask

Capture standing: 35 of 86 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.